Pedro Valdivielso

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Occupation-Related Differences in the Prevalence of Metabolic Syndrome

Miguel-Ángel Sánchez-Chaparro, Eva Calvo‐Bonacho, Arturo González‐Quintela et al. · Diabetes Care · 2008 · 92 citations · Full text

Veterinary Medicine, Endocrinology, Metabolic Physiology +15

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report

Pedro Valdivielso, José Rioja, Carlota García-Arias et al. · Cardiovascular Diabetology · 2009 · 72 citations · Full text

Life Sciences, Nutritional Sciences, Pharmacotherapy +16

Additive effects of LPL, APOA5 and APOEvariant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study

María José Ariza, Miguel-Ángel Sánchez-Chaparro, Francisco Javier Barón-López et al. · BMC Medical Genetics · 2010 · 67 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16